Evommune Inc EVMN

$6.92 -0.29 (-4.02%)

Valuation

Market cap
251,141,000
Revenue TTM
$13,000,000
Net income TTM
$-68,870,000
PE ratio
0.00
Forward PE
—
Profit margin
-529.77%
Debt to equity
0.00

Trading

Volume
1,745,400
Avg volume
647,298
Day's range
$6.74 – $7.28
Shares out
36,292,000
Stochastic %K
6%
Beta
—
Analysts
Strong Sell
Price target
$24.00

Price

Company profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The compan...

Show more

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(925) 247-4481
Website
https://www.evommune.com
Address
1891 Page Mill Road, Palo Alto, United States

Latest news

Stocktwits

prismmarketview Sep 9, 4:11 PM
PRISM Mid-Day Movers: Pharmaceuticals and Biotech are Today's Leaders. Opus Genetics, Inc. (NASDAQ: $IRD ) surged, up 26.5% to $5.49 today, rebounding sharply from yesterday’s $4.34 close. Pulse Biosciences, Inc. (NASDAQ: $PLSE ) climbed 18.24% to $57.69 today, gaining $8.90 from its previous $48.79 close. Other Notable Movers: bioAffinity Tech ($BIAF ) up 14% Skye Bioscience ($SKYE ) up 10% Evommune, Inc. ($EVMN ) down -16% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-biotech-are-todays-leaders/
0 replies
OpenOutcrier Sep 9, 12:17 PM
$EVMN (-10.1% pre) Evommune Halts Atopic Dermatitis Program Following Trial Failure https://ooc.bz/l/113610
0 replies
Mden Sep 9, 12:07 PM
$EVMN still holding up extremely well.
1 replies
topstockalerts Sep 9, 2:25 AM
Evommune released preliminary Phase 2b results for EVO756 in moderate-to-severe atopic dermatitis, a key clinical milestone that the company had identified for September 2026. The results appear to have disappointed investors, sending the stock sharply lower after the drug had already come under pressure following an earlier trial failure in chronic spontaneous urticaria. In June, EVO756 failed to meet the primary endpoint in its Phase 2b urticaria trial at any tested dose, leading Evommune to discontinue development in that indication. The setback prompted William Blair to downgrade the stock to Market Perform and weakened investor confidence ahead of the atopic dermatitis data. $EVMN
0 replies
DonCorleone77 Sep 9, 12:57 AM
$CASY $BNED $EVMN $TH $INGM AFTER-HOURS MOVERS: Currently Higher After Earnings: - InnovAge Holding (INNV) up 9.5% Currently Also Higher: - Chime Financial (CHYM) up 9.0% after acquisition of Stride Bank and raised guidance Currently Lower After Earnings: - ServiceTitan (TTAN) down 20.3% - MIND Technology (MIND) down 13.3% - Braze (BRZE) down 12.3% - Casey's General Stores (CASY) down 8.3% - Barnes & Noble Education (BNED) down 1.9% Currently Also Lower: - Evommune (EVMN) down 15.8% after EV0756 trial did not meet primary and secondary endpoints - Target Hospitality (TH) down 6.9% after equity offering - Ingram Micro (INGM) down 6.3% after equity offering.
0 replies
StocktwitsNews Sep 8, 11:51 PM
Why Is EVMN Stock Down 13% After-Hours? $EVMN $VTI $IWM https://stocktwits.com/news/equity/markets/why-is-evmn-stock-down-13-after-hours/cZtEX8dRJy7
0 replies
MasterOfMyDomains Sep 8, 11:42 PM
$EVMN for now….
0 replies
Mden Sep 8, 11:13 PM
$EVMN less than15% price drop, not too bad after drug failure
1 replies